tralokinumab   Click here for help

GtoPdb Ligand ID: 8001

Synonyms: Adbry® | Adtralza® | BAK1.1 [2] | CAT-354 [2] | tralokinumab-ldrm
Approved drug Immunopharmacology Ligand
tralokinumab is an approved drug (EMA & FDA (2021))
Compound class: Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Immunopharmacology Disease
Disease X-Refs Comment References
Atopic dermatitis Disease Ontology: DOID:3310
OMIM: 603165
Phase 3 clinical candidate for atopic dermatitis (see NCT03131648).
Alopecia areata Disease Ontology: DOID:986
Phase 2 clinical candidate for alopecia areata (see NCT02684097).
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Phase 3 clinical candidate for uncontrolled asthma (see NCT02161757).